Entasis Therapeutics Announces the Appointment of Elizabeth Keiley as General Counsel
16 avr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019
10 avr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...
Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
04 avr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious...
Entasis Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Conference in London
02 avr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports Full Year 2018 Financial Results and Provides Business Update
29 mars 2019 07h30 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference
06 mars 2019 16h01 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Receives Positive Feedback from FDA End-of-Phase 2 Meeting for ETX2514SUL; Signs Rapid Diagnostic Agreement with bioMérieux
05 févr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
05 déc. 2018 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial...
Entasis Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
14 nov. 2018 08h00 HE
|
Entasis Therapeutics Holdings Inc.
Completed $75.0 million initial public offering in September Reported positive Phase 2 topline results of lead program ETX2514SUL On-track to initiate two Phase 3 clinical trials in 2019 WALTHAM,...
Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in The New England Journal of Medicine
07 nov. 2018 17h00 HE
|
Entasis Therapeutics Holdings Inc.
Zoliflodacin Was Well-Tolerated and Successfully Treated Substantially All Uncomplicated Gonorrhea Cases Phase 3 clinical trial, in partnership with GARDP, to begin in 2019 WALTHAM, Mass., Nov. 07,...